36. Epidermolysis bullosa Clinical trials / Disease details

Clinical trials : 160 / Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-010763-17-SE (EUCTR)	26/05/2009	20/03/2009	Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia congenita-a double-blind placebo-controlled phase II proof of concept study	Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia congenita-a double-blind placebo-controlled phase II proof of concept study	Epidermolysis Bullosa Simplex and Pachyonychia Congenita	Trade Name: Dysport	Sophiahemmet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Sweden
2	NCT00936533 (ClinicalTrials.gov)	May 2009	8/7/2009	Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita	Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita - a Double-blind Placebo-controlled Phase II Proof of Concept Study	Epidermolysis Bullosa Simplex	Drug: Dysport ® (Botulinumtoxin A (Btx A));Drug: Placebo	Uppsala University	NULL	Recruiting	16 Years	N/A	Both	40	Phase 2	Sweden